Figures & data
Figure 1 Time course of HbA1c in a 12 week core study and a 40 week extension study when vildagliptin (LAF; 50 mg once daily) was given as add-on to metformin (MET). PBO = placebo. Reproduced from CitationAhrén et al 2004a after permission from the American Diabetes Association.
Figure 2 Time course of mean HbA1c levels during 24 week treatment with vildagliptin at 50 mg daily (Δ) or 100 mg daily (▲) or placebo (○) in patients with type 2 diabetes continuing stable metformin treatment (≥1.5 g daily). Reproduced from Bosi et al 2007 after permission from the American Diabetes Association.
Figure 3 Time course of mean HbA1c levels during 24 week treatment with sitagliptin (100 mg once daily; ●) or placebo (○) in patients with type 2 diabetes with on-going treatment with (≥1.5 g daily). Reproduced from Charbonnel et al 2006 after permission from the American Diabetes Association.
Figure 4 Changes in HbA1c, fasting and 2 h prandial glucose and insulin secretion (as determined by 2 hr AUCinsulin divided by AUCglucose after a meal tolerance test) after 24 weeks treatment of sitagliptin and/or metformin, as indicated in bottom. Results reported are adjusted for changes after treatment with placebo. fig. is drawn after results reported in CitationGoldstein et al 2007.
Figure 5 Insulin secretion (evaluated as the 30 min suprabasal AUCC-peptide following meal ingestion divided by the 30 min increase in glucose), insulin sensitivity (evaluated by the OGIS estimation) and adaptation index (insulin secretion times insulin sensitivity) at baseline and after 12, 24 and 52 weeks of treatment with vildagliptin at 50 mg daily in combination with metformin (n = 31) versus treatment with metformin (n = 26). Low right panel shows the change in HbA1c after the 52 week treatment period as a function of change in adaptation index in the same study. Reproduced from CitationAhrén et al 2005 after permission from the American Diabetes Association.
